These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 21074059)

  • 21. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
    Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
    Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
    Kirkwood JM; Lorigan P; Hersey P; Hauschild A; Robert C; McDermott D; Marshall MA; Gomez-Navarro J; Liang JQ; Bulanhagui CA
    Clin Cancer Res; 2010 Feb; 16(3):1042-8. PubMed ID: 20086001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.
    Ribas A; Comin-Anduix B; Economou JS; Donahue TR; de la Rocha P; Morris LF; Jalil J; Dissette VB; Shintaku IP; Glaspy JA; Gomez-Navarro J; Cochran AJ
    Clin Cancer Res; 2009 Jan; 15(1):390-9. PubMed ID: 19118070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antibody therapies for melanoma].
    Kiniwa Y; Okuyama R
    Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
    Chung KY; Gore I; Fong L; Venook A; Beck SB; Dorazio P; Criscitiello PJ; Healey DI; Huang B; Gomez-Navarro J; Saltz LB
    J Clin Oncol; 2010 Jul; 28(21):3485-90. PubMed ID: 20498386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
    Ribas A; Chesney JA; Gordon MS; Abernethy AP; Logan TF; Lawson DH; Chmielowksi B; Glaspy JA; Lewis K; Huang B; Wang E; Hsyu PH; Gomez-Navarro J; Gerhardt D; Marshall MA; Gonzalez R
    J Transl Med; 2012 Nov; 10():236. PubMed ID: 23171508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
    Fong L; Small EJ
    J Clin Oncol; 2008 Nov; 26(32):5275-83. PubMed ID: 18838703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nivolumab for metastatic melanoma-basic knowledge and clinical data].
    Yamazaki N; Maeda Y
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
    Callahan MK; Wolchok JD; Allison JP
    Semin Oncol; 2010 Oct; 37(5):473-84. PubMed ID: 21074063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
    Tarhini AA; Kirkwood JM
    Curr Opin Mol Ther; 2007 Oct; 9(5):505-14. PubMed ID: 17932815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
    Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
    Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biology and clinical applications of CD40 in cancer treatment.
    Fonsatti E; Maio M; Altomonte M; Hersey P
    Semin Oncol; 2010 Oct; 37(5):517-23. PubMed ID: 21074067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
    Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
    N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
    Ascierto PA
    Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immune checkpoint antibodies increase survival in patients with metastatic melanoma].
    Fløe LE; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(33):. PubMed ID: 27550784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers.
    Page DB; Yuan J; Wolchok JD
    Immunotherapy; 2010 May; 2(3):367-79. PubMed ID: 20635901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy.
    Margolin KA; Di Giacomo AM; Maio M
    Semin Oncol; 2010 Oct; 37(5):468-72. PubMed ID: 21074062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
    Reuben JM; Lee BN; Li C; Gomez-Navarro J; Bozon VA; Parker CA; Hernandez IM; Gutierrez C; Lopez-Berestein G; Camacho LH
    Cancer; 2006 Jun; 106(11):2437-44. PubMed ID: 16615096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.